| Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. | |
| | |
MedLine Citation:
|
PMID: 12771608 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To report on the incidence and risk factors associated with the development of ischemic skin lesions (ISL) in critically ill patients with catecholamine-resistant vasodilatory shock treated with a continuous infusion of arginine-vasopressin (AVP). DESIGN: Retrospective analysis. SETTING: Twelve-bed general and surgical intensive care unit in a university hospital. PATIENTS: A total of 63 critically ill patients with catecholamine-resistant vasodilatory shock. INTERVENTIONS: Continuous AVP infusion. MEASUREMENTS AND MAIN RESULTS: Demographic, hemodynamic, laboratory data, and skin status were evaluated 24 hrs before and during AVP therapy (24 and 48 hrs). Patients were grouped according to development of new ISL during AVP therapy. A mixed-effects model was used to compare groups. A multiple logistic regression analysis was used to identify independent risk factors for the development of ISL. ISL developed in 19 of 63 patients (30.2%). Thirteen of 19 patients (68%) developed ISL in distal limbs, two patients (10.5%) developed ISL of the trunk, four patients (21%) developed ISL in distal limbs and in the trunk. Five patients (26%) had additional ischemia of the tongue. Body mass index, preexistent peripheral arterial occlusive disease, presence of septic shock, and norepinephrine requirements were significantly higher in patients developing ISL. ISL patients received significantly more units of fresh frozen plasma and thrombocyte concentrates than patients without ISL. Preexistent peripheral arterial occlusive disease and presence of septic shock were independently associated with the development of ISL during AVP therapy. CONCLUSIONS: ISLs are a common complication during continuous AVP infusion in patients with catecholamine-resistant vasodilatory shock. The presence of septic shock and a history of peripheral arterial occlusive disease are independent risk factors for the development of ISL. |
| | |
Authors:
|
Martin W Dünser; Andreas J Mayr; Andreas Tür; Werner Pajk; Friesenecker Barbara; Hans Knotzer; Hanno Ulmer; Walter R Hasibeder |
Related Documents
:
|
660698 - The use of microscopy as a guide to primary excision of high-tension electrical burns. 8456588 - Bone disease in burn patients. 864088 - The use of transcutaneous oxygen electrodes in intensive therapy. 8362468 - Relations between mixed venous oxygen saturation and hemodynamic variables in patients ... 1524478 - Effect of nissen fundoplication on esophageal motor function. 12614208 - Acute basophilic leukaemia: eight unsuspected new cases diagnosed by electron microscopy. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Critical care medicine Volume: 31 ISSN: 0090-3493 ISO Abbreviation: Crit. Care Med. Publication Date: 2003 May |
Date Detail:
|
Created Date: 2003-05-28 Completed Date: 2003-06-16 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0355501 Medline TA: Crit Care Med Country: United States |
Other Details:
|
Languages: eng Pagination: 1394-8 Citation Subset: AIM; IM |
Affiliation:
|
Department of Anesthesia and Critical Care Medicine, Leopold Franzens University of Innsbruck, Austria. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Analysis of Variance Arginine Vasopressin / administration & dosage, adverse effects* Arterial Occlusive Diseases / complications Austria / epidemiology Body Mass Index Drug Resistance Female Hospitals, University Humans Incidence Infusions, Intravenous Ischemia / chemically induced*, epidemiology, therapy Logistic Models Male Middle Aged Multiple Organ Failure / complications Norepinephrine / administration & dosage, adverse effects* Retrospective Studies Risk Factors Shock / complications, drug therapy*, metabolism Skin / blood supply* Vasoconstrictor Agents / administration & dosage, adverse effects* |
| Chemical | |
Reg. No./Substance:
|
0/Vasoconstrictor Agents; 113-79-1/Arginine Vasopressin; 51-41-2/Norepinephrine |
| Comments/Corrections | |
Comment In:
|
Crit Care Med. 2003 May;31(5):1587-8
[PMID:
12771642
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Albumin-adjusted calcium is not suitable for diagnosis of hyper- and hypocalcemia in the critically ...
Next Document: Usefulness of left ventricular stroke volume variation to assess fluid responsiveness in patients wi...